

10/02/00
Jc931 U.S. PTO
09/676620

10-03-00

A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: RICHTER ET AL.
Docket: 163.1406US01
Title: ANTIMICROBIAL COMPOSITIONS FORMULATED FOR USE IN COLD TEMPERATURE CONDITIONS AND METHODS OF USE THEREOF

Jc931 U.S. PTO
09/676620
10/02/00

CERTIFICATE UNDER 37 CFR 1.10

'Express Mail' mailing label number: EL674898202US

Date of Deposit: October 2, 2000

I hereby certify that this paper or fee is being deposited with the United States Postal Service 'Express Mail Post Office To Addressee' service under 37 CFR 1.10 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

By: *Linda McCormick*

Name: *Linda McCormick*

BOX PATENT APPLICATION
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

We are transmitting herewith the attached:

- ☒ Transmittal sheet, in duplicate, containing Certificate under 37 CFR 1.10.
- ☒ Utility Patent Application: Spec. 33 pgs; 37 claims; Abstract 1 pgs.:
- ☒ An unsigned Combined Declaration and Power of Attorney
- ☒ Return postcard
- ☒ **PAYMENT OF THE FILING FEE IS BEING DEFERRED.**

MERCHANT & GOULD P.C.

P.O. Box 2903, Minneapolis, MN 55402-0903
(612) 332-5300

By: *J. Scot Wickhem*

Name: J. Scot Wickhem

Reg. No.: 41,376

Initials: JSW:PSTpmc



23552

PATENT TRADEMARK OFFICE

5 **ANTIMICROBIAL COMPOSITIONS FORMULATED FOR USE IN COLD
 TEMPERATURE CONDITIONS AND METHODS OF USE THEREOF**

Field of the Invention

 The present invention is directed to antimicrobial compositions having
10 specialized benefit of skin protection and conditioning for the control of mastitis in
 milk producing animals that is especially useful in cold temperature environments and
 a method of treating for mastitis in cold temperature conditions. Furthermore, in
 some embodiments, the invention provides mastitis treatment compositions and
 formulations having specialized benefit of skin protection and conditioning on the
15 teats of an animal that are already in poor health. In one preferred embodiment, the
 invention provides teat dip formulations comprising a carboxylic acid, typically a fatty
 acid, and a carrier medium including a freezing point depressing component.

Background of the Invention

20 Mastitis is an inflammation of the mammary gland. Bovine mastitis is the
 most common and most costly disease affecting dairy herds. Some estimates suggest
 at least half of the dairy animal population have some degree or form of mastitis.
 This condition results in lowered milk yield and reduced milk quality. Economic loss
 to mastitis in the U.S. is estimated at about \$1.8 billion or approximately 10% of total
25 milk sales with about two-thirds of this loss due to reduced milk production from
 infected cows. In dairy cattle, mastitis typically results from microorganisms; usually

bacteria, that invade the udder, multiply in the milk producing tissues, and synthesize toxins, a by-product of bacterial metabolism. The characteristic features of inflammation are swelling, heat, redness, pain and disturbed function.

While the animal immune system can fight intramammary infections, many
5 chronic infections remain sub-clinical (asymptomatic) and undetected unless diagnosed by laboratory testing. Sub-clinical mastitis can result in a reservoir of microorganisms, which can lead to the infection of other animals within the herd. More than 80 species of microorganisms have been identified as causal agents, although approximately 95% of mastitis is caused by four pathogens: *Staphylococcus*
10 *aureus*, *Streptococcus agalactiae*, *Streptococcus dysagalactiae*, and *Streptococcus uberis*. Mastitis causing pathogens fall into two categories namely contagious and environmental. Contagious bacteria, such as *Streptococcus agalactiae* and *Staphylococcus aureus*, primarily colonize host tissue sites such as mammary glands, teat canals, teat skin lesions etc. and are spread from one infected cow to another
15 during the milking process. Environmental bacteria, often streptococci, enterococci and coliform organisms, are commonly present within the cow's surroundings from sources such as cow feces, soil, plant material, bedding or water, and infect by casual opportunistic contact with an animal. This distinction, although not exclusive, is of practical importance because different dairy herd maintenance measures are needed
20 for the different groups of microorganisms. In all bovine mastitis cases, whatever the causal microorganism, the route of transmission of the invading pathogen into the inner gland of the udder is through the teat orifice and teat canal.

Management of dairy herds focuses attention on treatment of both established mastitis and on prevention of new intramammary infections. Therapy and hygiene are two fundamental components of an effective mastitis control program. Each is applied in concert, and each operates independently. The primary effect of therapy is to eliminate established infections, whereas, hygiene reduces the incidence of new infection by interrupting transmission vectors. A non-exhaustive list of ancillary factors which may be employed for the elimination and prevention of mastitis, include, post-lactation antibiotic infusion into the udder (e.g., dry cow treatment); and, post-milking teat antisepsis or "teat dipping" during lactation.

- 10 Researchers agree, and an abundance of published evidence supports the concept, that dipping teats into an effective antimicrobial solution immediately after each milking is the single most effective procedure for decreasing new intramammary infections in lactating cows. Between 1955 to 1970, Dodd and co-workers conducted extensive epidemiologic investigations in commercial dairy herds (F. K. Neave, F. H. Dodd, and R. G. Kingwell, 1966, "A Method of Controlling Udder Disease", Vet. Rec. 78:521; F. K. Neave, F. H. Dodd, R.G. Kingwell and D. R. Westgarth, 1969, "Control of Mastitis in the Dairy Herd by Hygiene and Management", J. Dairy Sci. 52:696; F. H. Dodd, D. R. Westgarth, F. K. Neave and R. G. Kingwill, 1969, "Mastitis - The Strategy of Control", J. Dairy Sci. 52:689; and F. H. Dodd, and F. K. Neave, 1970, "Mastitis Control", Proceedings, Nat'l. Inst. Res. Dairying, pp. 21-60). From this work, they developed the conceptual basis for modern mastitis control methods of which teat dipping is an integral component. The efficacy and value of teat dipping has since been confirmed in dozens of field trials, and it is now accepted

that an effective teat dip can reduce the incidence of new intramammary infections at least 50% and often up to 90%.

To reduce mastitis, commercial teat dips have been developed containing a variety of antimicrobial agents including iodophors, quaternary ammonium compounds, chlorhexidine salts, chlorine release compounds (e.g. alkali hypochlorites), oxidizing compounds (e.g. hydrogen peroxide, peracids), protonated carboxylic acids (e.g. octanoic, nonanoic, decanoic, acids), acid anionics (e.g. alkylaryl sulfonic acids), and chlorine dioxide (from chlorite). These agents, which have varying degrees of effectiveness, limit the transmission of mastitis by reducing pathogen populations on the teat. Teat dips, can also be divided into two broad classifications. The Class I type are antimicrobial and are applied to kill microorganisms already present in the teat canal or on the surface of the teat skin. By design, their microbiological effect is immediate and they primarily target the contagious organisms that are vectored between animals during the pre-milking, milking and post-milking process. The Class II type teat dip, often referred to as a “teat sealer,” is a film-forming or coating composition which may or may not be antimicrobial; and, functions by developing a residual protective barrier on the teat thus providing prophylaxis by sealing the teat orifice from environmental contamination. The film, which forms on the surface of the teat, serves as a physical barrier through which mastitis causing pathogens cannot penetrate during the intermilking period.

General disclosures of teat dip technology are shown in, for example, “Current Concepts of Bovine Mastitis.” 1996, Fourth Ed. National Mastitis Council,

4,049,830, issued September 20, 1977; and Andrews et al., U. S. Pat. No.

4,113,854, issued September 12, 1978. One disadvantage of many such film-forming agents is their tendency to form a "hard" film, which is tenacious and often difficult to remove.

5 There is a growing acceptance among academics, veterinarians and dairy herd management that proactive maintenance of teat health and skin condition is an integral part of a complete program for the prevention, control and remedial correction of mastitis in milk producing animals. A growing number of publications support this (see for example, M.D. McKinzie and T.C. Hemling, 1995, "The Effect of Teat Skin
10 Condition on Milk Yield and Milkout Time", National Mastitis Council Proceedings, pp 160-163; L.K Fox, 1992, "Colonization of Staphylococcus Aureus On Chapped Skin: Effect of Iodine and Chlorhexidine Postmilking Teat Disinfectants", J. Dairy Sci. 75:66; and JJ Goldbert et al., 1994, "Evaluation of Teat Conditioning Qualities of Postmilking Teat Dips", National Mastitis Council technology transfer Session,
15 Orlando, FL. The assertion is that a healthy milk delivery organ can naturally retard and more readily withstand the adverse affects of infection.

 Although many teat dip products are available, and there remains a continuing need for new and effective teat dip compositions having immediate and long lasting antimicrobial effect against a wide spectrum of mastitis causing organisms; there is
20 need for such antimicrobial compositions which additionally provide superior skin conditioning and health maintenance functions.

 Additionally, many teat dip products are not conducive for use in cold environment conditions. For example, many teat dip compositions include a large

amount of water, and can freeze in cold environments. Such compositions can freeze on the teats, and cause irritation, chapping and frostbite, and such conditions can enhance the incidence of mastitis caused by opportunistic invasive microorganisms.

Thus, although many teat dip products are available, there is a continuing need
5 for new and effective teat dip compositions having immediate and long lasting antimicrobial effect against a wide spectrum of mastitis causing organisms that are formulated for use in cold environments.

Summary of the Invention

10 The present invention is directed to novel antimicrobial compositions, which can be used as a teat dip for milk producing animals. At least some embodiments of this invention provide both superior antimicrobial protection against mastitis causing organisms and skin conditioning for maintenance of healthy teats; and in addition provide protection against the adverse affects of frigid weather, one of the major
15 causes of irritation, chapping and frostbite, which enhance the incidence of mastitis caused by opportunistic invasive microorganisms. Still further benefit is accomplished by application of at least some preferred compositions of this invention on teats which are already in poor health condition, for example by application on so-termed "hospital pen animals", to facilitate faster repair and the healing process.

20 It will be noted that at several places throughout the Specification, guidance is provided through lists of examples. In each instance, the recited lists serve only as representative groups. It is not meant, however, that the lists are exclusive.

In general, the invention also includes a method of controlling mastitis in milk producing animals comprising applying the composition to a teat of an animal. The composition of the invention is particularly beneficial when applied in colder environmental temperatures, for example in temperatures of below 40°F.

5

Detailed Description of the Invention

The present invention is directed to antimicrobial compositions. In general, the compositions include a fatty acid, typically a C₆-C₁₂ fatty acid and a carrier medium including a freezing point depressant component. As used herein, "freezing point depressant component" means a constituent or mixture of constituents within the composition that act to reduce the freezing point of the composition below that of the composition without that constituent. Typically, the freezing point depressant component acts to reduce the freezing point of the composition below the freezing point of water. The compositions of the invention can be advantageously used as a teat dip for control of mastitis in milk producing animals. The compositions of the invention are formulated for use in cold temperature environments, for example in environments having a temperature of 40°F or below. However, formulating of the invention can also be used in warm environment conditions. Some embodiments are particularly useful to facilitate faster repair of teats that are already in poor health regardless of the temperature. For example, some embodiments are particularly beneficial on chapped or irritated teats.

Components Used in a Teat Dip Embodiment of the Invention

The compositions of the invention can be formulated as a teat dip for mastitis prevention or control. According to this embodiment, the compositions can comprise a carboxylic acid, such as a fatty acid in a carrier medium comprising a freezing point
5 depressant component. Preferably, the fatty acid comprises in the range of 0.01 to 5% by wt. of the total composition, and the freezing point depressant component comprises greater than 60% by wt. of the total composition.

Teat dip compositions may optionally also include, a rheology modifier or admixture, a film-forming agent or admixture, a buffer system, a hydrotrope, a
10 coupler or admixtures thereof, a surfactant or surfactant admixture, an emollient, a skin-conditioner or a lubricant or admixtures thereof, one or more adjuvants, etc. The preferred compositions of the invention comprise ingredients, which are generally regarded as safe, and are not of themselves or in admixture incompatible with milk or milk by-products. Ingredients may also be selected which are
15 cooperative in their combined effects whether incorporated for physical integrity of the formulation or to facilitate healing and overall health of the teat. The carrier functions to dilute the active ingredients and facilitate application to the intended surface.

The compositions of the invention can be provided as a ready-to-use
20 formulation or as concentrates, which are diluted prior to use. Hence, throughout this disclosure, reference will be made to "working compositions" which are the compositions, which are actually used as a teat dip. Thus, a working composition includes, for example, ready-to-use compositions as well as concentrates, which have

been diluted for use in a particular application. Methods for preparing concentrates based on the disclosure herein of working compositions are within the knowledge of one of skill in the art.

In preferred embodiments, a teat dip composition of the invention provides a protective soft barrier over the teat. A "soft barrier" provides a self annealing barrier which can flow to re-cover areas of the teat from which the dip may have been removed when the animal lays down, walks through the pasture or is subject to some other event which causes inadvertent removal of the dip. Advantageously, however, a herein disclosed soft barrier can also be readily removed from the teat using routine washing procedures prior to milking without congealing, pilling or leaving some other undesired residue on the teat. The soft barrier is provided and rheology modifiers described further below. Thus, unlike prior film-forming barriers, the protective soft barrier provided herein is a soft, non-peeling barrier that can undergo plastic deformation, for self-repair, without breaking or cracking.

Carrier Medium Including Freezing Point Depressant Component

The carrier medium of a composition of the invention can generally be an aqueous medium such as water, or an organic liquid such as an oil, a surfactant, an alcohol or polyol, an ester, an ether, or an organic or aqueous mixture of any of these. The carrier medium includes high concentrations of non-aqueous, preferably water miscible liquids or soluble solids that act as a freezing point depressant component for the composition. Preferred freezing point depressant components also have some degree of skin conditioning properties, and provide protection against the

adverse affects of frigid weather. Examples of preferred freezing point depressant components include polyols, and mixtures thereof. Preferred polyols include propylene glycol; glycerin; sorbitol; and homologs, homopolymers and derivatives thereof and mixtures thereof. Preferably, the freezing point depressant component of the carrier medium make up greater than 60%, in some embodiments, greater than 65%, in some other embodiments, greater than 70%, and in yet other embodiments, greater than 75% by weight of the total composition.

The freezing point depressant components within the composition have the desired effect of reducing the freezing point of the composition below that of water.

In some embodiments, the freezing point of the composition is below 25°F, in some embodiments, below 15°F, in some embodiments, below 10°F, in some embodiments below 0°F, in some embodiments below -10°F, and in yet other embodiments, below -20°F. By providing the composition with a low freezing point, the freezing point depressants allow the composition to be used in cold temperature environments, and help to prevent chapping, irritation, windburn, frostbite, and other such conditions on the teats of an animal associated with cold environments. Further, the compositions are less likely to freeze and can be applied in colder temperatures than many teat dips.

Fatty Acid

The compositions of the invention also include a carboxylic fatty acid component, which provides the antimicrobial activity. For optimal antimicrobial activity, the pH of the composition is preferably at or below the pKa of the fatty acid. Thus, in preferred compositions, the relationship of pH to pKa provides

antimicrobial activity through carboxylic fatty acids, which are substantially protonated. Preferred compositions of the invention have a pH in the range of about 3.5 to about 6.0, typically about 4.0 to about 5.0 and, in one preferred embodiment, about 4.5. Although a wider range of pH is possible, typically, below pH 3.5
5 undesirable skin irritation may occur and above pH 6.0 dissociation or conversion to the ionized form may reduce the antimicrobial efficacy of the fatty acid.

Fatty acids suitable for a composition of the present invention include C₆-C₁₂ fatty acids. Preferred fatty acids have a chain length from about C₇-C₉. One particularly preferred fatty acid is heptanoic acid that has seven carbon atoms,
10 including the carboxyl group, and has a pKa of 4.4. In addition to its preferred water solubility, heptanoic acid is not significantly irritating to the tissues.

In general, the fatty acid component of the invention can be present at about 0.01% to about 5.0% of the total weight of the working composition. For example, when heptanoic acid is the fatty acid, it may be present at about 0.01% to about 5%
15 of the total weight of the working composition. In a working composition having a pH of about 4.5, heptanoic acid may be present at about 0.1% to about 5% of the total working solution, preferably at about 0.5% to about 2.0%.

The antimicrobial components of the composition can be mixed in the carrier medium and include buffers, surface active agents and/or couplers to provide a pH
20 and solubility suitable for efficient bactericidal effect with low or no irritation to the tissues of the teat. The buffer system is present to prevent the likelihood of pH drift under typical use conditions. In general, the buffer system can include any weak acid and its conjugate base. Preferred bases used to adjust the pH of the compositions

include hydroxides of the alkaline earth metals, for example NaOH, KOH, LiOH, etc.

Maintenance of the pH of compositions described in this invention is preferred to minimize undesirable chemical changes, which may inhibit the microbiological efficacy of the antimicrobial components or cause toxic or irritating effect upon the teat. Any compatible organic or inorganic material or mixture of materials which has the desired effect of maintaining the composition pH within prescribed ranges can be utilized as the buffering agent or system in the invention. Factors which may cause undesirable pH shifts include the presence of naturally occurring chemicals brought into the composition, after application onto the teat, by skin exudations, milk or environmental soils; and, pH drifting which sometimes accompanies chemical equilibriums established within compositions as ingredients are changed or concentrations varied, for example, concentration changes which can occur as a teat dip dries on the teat.

In general, the pH of bovine mastitis control treatments can vary from a low of about pH 2.5 to a maximum of approximately 10.5 depending primarily upon the choice of antimicrobial agent being incorporated in the composition. Therefore the buffering agent or system is chosen accordingly. Most common commercially-available weak inorganic and organic acids can be used in the invention. Preferred weak inorganic acids include phosphoric acid and sulfamic acid. Useful weak organic acids include acetic acid, hydroxyacetic acid, citric acid, tartaric acid, lactic acid, glycolic acid, adipic acid, succinic acid, propionic acid, malic acid, alkane sulfonic acids, cycloalkane sulfonic acids, etc. Mixtures of organic and

inorganic acids can also be used. One typical and preferred buffer system is citric acid and its alkali metal salt.

Solubilizing agents called hydrotropes or couplers or solvents may be generally used in compositions of the invention to maintain physical single-phase integrity and storage stability. To this end, any number of ingredients known to those skilled in the formulation art may be employed, such as monofunctional and polyfunctional alcohols. These preferably contain from about 1 to about 6 carbon atoms and from 1 to about 6 hydroxy groups. Examples include ethanol, isopropanol, n-propanol, 1, 2-propanediol, 1, 2-butanediol, 2-methyl-2, 4-pentanediol, mannitol and glucose. Also useful are the higher glycols, polyglycols, polyoxides, glycol ethers and propylene glycol ethers. Additional useful hydrotropes include the free acids and alkali metal salts of sulfonated alkylaryls such as toluene, xylene, cumene and phenol or phenol ether or diphenyl ether sulfonates; alkyl and dialkyl naphthalene sulfonates and alkoxyated derivatives.

15 **Additional Components**

A composition of the invention may also contain one or more rheology modifiers, to enhance viscosity, or thicken the composition to facilitate adherence of a dip to the teat. Adherence enables the composition to remain in contact with transient and resident pathogenic bacteria for longer periods of time, promoting microbiological efficacy and resisting waste because of excessive dripping. The rheology modifier may be a film former or act cooperatively with a film-forming agent to form a barrier that provides additional protection. However, in preferred

embodiments, a teat dip composition of the invention provides a soft barrier, rather than a well-defined film.

Water soluble or water dispersible rheology modifiers that are useful can be classified as inorganic or organic. The organic thickeners can further be divided into
5 natural and synthetic polymers with the latter still further subdivided into synthetic natural-based and synthetic petroleum-based.

Inorganic thickeners are generally compounds such as colloidal magnesium aluminum silicate (VEEGUM®), colloidal clays (Bentonites), or silicas (CAB-O-SILS®) which have been fumed or precipitated to create particles with large surface to
10 size ratios. Suitable natural hydrogel thickeners are primarily vegetable derived exudates. For example, tragacanth, karaya, and acacia gums; and extractives such as carrageenan, locust bean gum, guar gum and pectin; or, pure culture fermentation products such as xanthan gum. Chemically, all of these materials are salts of complex
15 anionic polysaccharides. Synthetic natural-based thickeners having application are cellulosic derivatives wherein the free hydroxyl groups on the linear anhydro-glucose polymers have been etherified or esterified to give a family of substances, which dissolve in water and give viscous solutions. This group of materials includes the alkyl and hydroxylalkylcelluloses, specifically methylcellulose,
hydroxyethylmethylcellulose, hydroxypropylmethylcellulose,
20 hydroxybutylmethylcellulose, hydroxyethylcellulose, ethylhydroxyethylcellulose, hydroxypropylcellulose, and carboxymethylcellulose. Synthetic petroleum-based water soluble polymers are prepared by direct polymerization of suitable monomers of which polyvinylpyrrolidone, polyvinylmethylether, polyacrylic acid and

polymethacrylic acid, polyacrylamide, polyethylene oxide, and polyethyleneimine are representative.

A preferred rheology modifier is polyvinylpyrrolidone, K-90 manufactured by International Specialty Products. This rheology modifier is particularly advantageous
5 in that it is very water soluble, compatible in compositions containing high formula percentages of organic materials and is believed to retard skin irritation.

Suitable surfactants or surfactant admixtures can be selected from compatible water-soluble or water dispersible nonionic, or anionic surface-active agents; or mixtures of each or both types. Non-ionic surfactants useful in the invention are
10 generally characterized by the presence of an organic hydrophobic group and an organic hydrophilic group and are typically produced by the condensation of an organic aliphatic, alkyl aromatic or polyoxyalkylene hydrophobic compound with a hydrophilic alkaline oxide moiety which in common practice is ethylene oxide or a polyhydration product thereof, polyethylene glycol. Practically any hydrophobic
15 compound having a hydroxyl, carboxyl, amino, or amido group with a reactive hydrogen atom can be condensed with ethylene oxide, or its polyhydration adducts, or its mixtures with alkoxylenes such as propylene oxide to form a nonionic surface-active agent. The length of the hydrophilic polyoxyalkylene moiety which is condensed with any particular hydrophobic compound can be readily adjusted to yield
20 a water dispersible or water soluble compound having the desired degree of balance between hydrophilic and hydrophobic properties.

Useful nonionic surfactants in the present invention include:

Block polyoxypropylene-polyoxyethylene polymeric compounds based upon propylene glycol, ethylene glycol, glycerol and trimethylolpropane as the initiator reactive hydrogen compound. Examples of polymeric compounds made from a sequential propoxylation and ethoxylation of initiator are commercially available under the trade name PLURONIC[®] manufactured by BASF Corp. PLURONIC[®] compounds are difunctional (two reactive hydrogens) compounds formed by condensing ethylene oxide with a hydrophobic base formed by the addition of propylene oxide to two hydroxyl groups of propylene glycol. This hydrophobic portion of the molecule weighs from about 1,000 to about 4,000. Ethylene oxide is then added to sandwich this hydrophobe between hydrophilic groups, controlled by length to constitute from about 10% by weight to about 80% by weight of the final molecule.

Likewise useful nonionic surfactants include condensation products of one mole of a saturated or unsaturated, straight or branched chain alcohol having from about 6 to about 24 carbon atoms with from about 3 to about 50 moles of ethylene oxide. The alcohol moiety can consist of mixtures of alcohols in the above delineated carbon range or it can consist of an alcohol having a specific number of carbon atoms within this range. Examples of like commercial surfactant are available under the trade name NEODOL[®] manufactured by Shell Chemical Co. and ALFONIC[®] manufactured by Vista Chemical Co.

Condensation products of one mole of saturated or unsaturated, straight or branched chain carboxylic acid having from about 8 to about 18 carbon atoms with from about 6 to about 50 moles of ethylene oxide. The acid moiety can consist of

from environmental conditions such as frigid temperatures wind chill, dehydration, abrasion, windburn and sunburn. Any water miscible, soluble or dispersible skin-conditioning agent may be used in this invention. Compositions such as polyhydric alcohols are useful in the invention including glycerin, sorbitol, mannitol, and

5 propylene glycol and its homopolymers; fatty acid esters of simple monohydril alcohols including isopropyl palmitate or isopropyl myristate and similar esters; polyol esters of fatty acids; and, ethoxylated lanolins, vegetable oils, and similar natural sourced derivatives such as aloe. Preferred emollients to be used in the invention include glycerin, and propylene glycol and lanolin. It should be noted that

10 preferably the freezing point depressant component in the carrier medium also act as emollient/moisturizer/humectants. For example, in some preferable embodiments, propylene glycol and glycerin are present in high concentrations in the composition, and act as both freezing point depressants and emollients.

The compositions of the invention may also optionally include medicaments,

15 for example sunscreens such as paraamino benzoic acid and healing agents such as allantoin or tocopheryl acetate or α -hydroxy carboxylic acids or urea to provide curative action and stimulation of formation of new tissue; preservatives such as methyl paraben, propyl paraben, sorbic and benzoic acids or salts thereof to retard bacterial growth and prolong shelf life; antioxidants such as BHT (butylated

20 hydroxytoluene), BHA (butylated hydroxyanisole), TBHQ (tert-butylhydroquinone), or propyl gallate to retard oxidative or hydrolytic degradation; sequestering agents such as aminopolyacetates, polyphosphonates, aminopolyphosphonates,

polycarboxylates, and condensed phosphates; dispersants or suspending agents having polyelectrolytic character such as polyacrylate and similar polycarboxylates of homopolymeric or copolymeric structure; and manufacturing processing agents, for example defoam additives employed to facilitate blending and mixing.

- 5 The compositions can also include, dyes, pigments, marking agents, or other such components, as is generally known.

Preferred Methods of Using the Compositions

- 10 The compositions of the invention are useful in a method for controlling mastitis in milk producing animals. Generally, the method includes applying an antimicrobial composition embodying the invention a teat of an animal. Due to the freezing point depressant component within the composition, the compositions of the invention are particularly useful for methods wherein the antimicrobial composition is applied in environmental temperatures of below 40°F or is applied to the teat of an
- 15 animal that will be exposed to environmental temperatures of below 40°F within 12 hours of the application. In some embodiments of such methods, the environmental temperatures can be below 30°F, below 20°F, or below 10°F.

- 20 Although the compositions of the invention are generally formulated for use in colder environmental temperatures, as discussed above, at least some embodiments of the compositions can be used in methods of treating teats on a milk producing animal which are already in poor health condition, for example by application on so-termed "hospital pen animals", to facilitate faster repair and the healing process.

The following examples are provided to further describe certain advantageous compositions according to the invention. The Examples, however, are not intended to limit the scope of the compositions within the spirit and scope of the invention.

5

Examples

Example 1 **Formulation of Teat Dip Composition**

The present Example provides one procedure for preparing a working composition of a teat dip composition according to one embodiment of the invention.

This procedure can be used regardless of the total weight of the composition

10 formulated. Thus, while a particular weight percentage of a component may vary among formulations, the procedure used for mixing the components is the same. It will be appreciated that other procedures can be used and are within the knowledge of one skilled in the art.

Deionized water is added to a stainless steel tank having a variable speed
15 pitched blade turbine. The tank is agitated and the surfactant, sodium dioctylsulfosuccinate, is then added, with about 15 minutes of mixing and allowed to solubilize the surfactant. Polyvinylpyrrolidone K-90 is charged and mixed until completely solubilized. Preferably, the Polyvinylpyrrolidone is completely solubilized prior to addition of subsequent components.

20 Propylene glycol (technical), glycerin (e.g., 96% USP), ethoxylated lanolin, the fatty acid (e.g., heptanoic acid) and the fragrance, methyl solicylate are added and mixed for about 15 minutes to incorporate them into the mixture. A buffer, such as anhydrous granular citric acid is slowly added to the mixture and mixed until

[illegible]

5

according to the invention.

Table 1: Teat Dip Formulation 1

ITEM	RAW MATERIAL	RM CODES	WT %
1	DI Water	100032	18.776
2	Sodium Dioctylsulfosuccinate, (AEROSOL OT-100) -----Dioctylsulfosuccinate	171000	0.020
3	Polyvinylpyrrolidone (Tradename PVP K-90)	230076	0.500
4	Propylene Glycol, Technical	164079	63.000
5	Glycerine, 96% USP	164186	15.000
6	Ethoxylated Lanolin, 75 EO., (Laneto 50)	172002	0.100
7	Heptanoic Acid	190454	1.750
8	Methyl Salicylate	261016	0.050
9	Citric Acid, Anhyd., Technical	124032	0.500
10	Potassium Hydroxide, 45% Liquid	114041	0.289
11	FD&C Blue # 1 (Food Blue # 2)	271411	0.015
			100.000

Polyvinylpyrrolidone(PVP K90): International Specialty Products, Wayne, N.J.

Aerosol OT: Cytec Industries, Inc., West Paterson, N.J.

Laneto 50: R.I.T.A. Corp., Woodstock, IL.

Table 2: Teat Dip Formulations 2-9

ITEM	RAW MATERIAL	RM CODES	2	3	4	5	6	7	8	9
			WT %	WT %	WT %	WT %	WT %	WT %	WT %	WT %
1	DI Water	100032	22.650	22.503	23.347	22.498	23.347	23.350	23.355	23.400
2	Neodol 25-9	173534	0.100	0.100	0.100					
3	AEROSOL OT	171000				0.100	0.100	0.100	0.100	0.100
4	Propylene Glycol	164079	75.000	75.000	75.000	75.000	75.000	75.000	75.000	75.000
5	Heptanoic Acid, C-7	190454	1.500	1.500	1.500	1.500	1.500	1.500	1.500	1.500
6	Lactic Acid, 88%	810432	0.750	0.897		0.902				
7	Phosphoric Acid, 75%	121012			0.053		0.053	0.050	0.045	
		Total	100.000	100.000	100.000	100.000	100.000	100.000	100.000	100.000

Neodol 25-9: Shell Chemical Co., Houston, TX.

Table 3: Teat Dip Formulations 10-17

ITEM	RAW MATERIAL	RM CODES	10	11	12	13	14	15	16	17
			WT %	WT %	WT %	WT %	WT %	WT %	WT %	WT %
1	DI Water	100032	23.393	23.375	23.325	23.313	23.307	20.340	23.250	20.350
2	Neodol 25-9	173534								
3	AEROSOL OT	171000	0.100	0.100	0.100	0.100	0.100	0.020	0.100	0.100
4	PVP K-90	230076							0.100	
5	Rheothik 80 -11, 16%									3.000
6	Propylene Glycol	164079	75.000	75.000	75.000	75.000	75.000	73.000	75.000	75.000
7	Glycerine, 96%	164186						5.000		
8	Laneto 50	810762						0.100		
9	Heptanoic Acid, C-7	190454	1.500	1.500	1.500	1.500	1.500	1.500	1.500	1.500
10	Phosphoric Acid, 75%	121012				0.045	0.048	0.040	0.050	0.050
11	KOH, 45%	114041	0.007	0.025	0.075					
12	FD&C Yellow # 6	810739				0.042	0.045			
		Total	100.000	100.000	100.000	100.000	100.000	100.000	100.000	100.000

Rheothik 80-11: Henkel Corp, Chemicals Group Care Chemicals, Ambler, PA

Table 4: Teat Dip Formulations 18-25

ITEM	RAW MATERIAL	RM CODES	18	19	20	21	22	23	24	25
			WT %	WT %	WT %	WT %	WT %	WT %	WT %	WT %
1	DI Water	100032	19.553	19.503	19.503	19.503	19.453	19.513	19.463	19.517
2	AEROSOL OT	171000	0.020	0.020	0.020	0.020	0.020	0.020	0.020	0.020
3	Rheothik 80 -11, 16%		0.750	0.750	0.750	0.750	0.750	0.750	0.750	0.750
4	Propylene Glycol	164079	73.000	73.000	73.000	73.000	73.000	73.000	73.000	73.000
5	Glycerine, 96%	164186	5.000	5.000	5.000	5.000	5.000	5.000	5.000	5.000
6	Laneto 50	810762	0.100	0.100	0.100	0.100	0.100	0.100	0.100	0.100
7	Heptanoic Acid, C-7	190454	1.500	1.500	1.500	1.500	1.500	1.500	1.500	1.500
8	KOH, 45%	114041	0.077	0.077	0.077	0.077	0.077	0.077	0.077	0.077
9	Benzaldehyde	283028		0.050				0.050		0.030
10	Vanillin	260607				0.050	0.100		0.050	
11	FD&C Blue # 1	810184						0.010	0.010	0.006
12	FD&C Red # 3	274449						0.030	0.030	
		Total	100.000	100.000	100.000	100.000	100.000	100.000	100.000	100.000

Table 5: Teat Dip Formulations 26-33

ITEM	RAW MATERIAL	RM CODES	26	27	28	29	30	31	32	33
			WT %	WT %	WT %	WT %	WT %	WT %	WT %	WT %
1	DI Water	100032	20.118	20.099	20.160	19.179	19.133	19.152	19.194	19.312
2	AEROSOL OT	171000	0.020	0.020	0.020	0.020	0.020	0.020	0.020	0.020
3	KLUCCEL HF	230151	0.100	0.100	0.100					
4	PVP K-90	230076				1.000	1.000	1.000	1.000	1.000
6	Propylene Glycol	164079	73.000	73.000	73.000	73.132	73.132	73.132	73.132	73.000
7	Glycerine, 96%	164186	5.000	5.000	5.000	5.000	5.000	5.000	5.000	5.000
8	Laneto 50	810762	0.100	0.100	0.100	0.100	0.100	0.100	0.100	0.100
9	Heptanoic Acid, C-7	190454	1.500	1.500	1.500	1.500	1.500	1.500	1.500	1.500
10	Phosphoric Acid, 75%	121012	0.012	0.012	0.012					
11	KOH, 45%	114041	0.008	0.008	0.008	0.004	0.004	0.004	0.004	0.003
12	Benzaldehyde	283028				0.050	0.050	0.050	0.050	
13	Vanillin	260607	0.100	0.100	0.100					
14	Methyl Salicylate	261016								0.050
15	FD&C Yellow # 5	271684	0.002	0.060			0.060	0.002		
16	FD&C Blue # 1	810184		0.001		0.015	0.001			0.015
17	FD&C Red # 3	274449	0.040					0.040		
		Total	100.000	100.000	100.000	100.000	100.000	100.000	100.000	100.000

Table 6: Teat Dip Formulations 34-41

[illegible]

Klucel HF: Hercules Inc., Aqualon Div., Wilmington, DE

Table 7: Teat Dip Formulations 42-47

ITEM	RAW MATERIAL	RM CODES	42	43	44	45	46	47
			WT %	WT %	WT %	WT %	WT %	WT %
1	DI Water	100032	18.676	18.543	19.298	19.167	18.790	18.776
2	AEROSOL OT	171000	0.020	0.020	0.020	0.020	0.020	0.020
3	PVP K-90	230076	1.000	1.000	0.499	0.500	0.500	0.500
4	Propylene Glycol	164079	63.000	63.000	62.897	63.000	63.000	63.000
5	Glycerine, 96%	164186	15.000	15.000	14.975	15.000	15.000	15.000
6	Laneto 50	810762	0.100	0.100	0.100	0.100	0.100	0.100
7	Heptanoic Acid, C-7	190454	1.500	1.500	1.498	1.500	1.750	1.750
8	KOH, 45%	114041	0.139	0.272	0.150	0.148	0.290	0.289
9	Citric Acid, Anhyd.	124032	0.500	0.500	0.499	0.500	0.500	0.500
10	Methyl Salicylate	261016	0.050	0.050	0.050	0.050	0.050	0.050
11	FD&C Blue # 1	810184	0.015	0.015	0.015	0.015		0.015
		Total	100.000	100.000	100.000	100.000	100.000	100.000

Example 2 Sanitizing Efficacy of Teat Dip KX-6128 against Eight Mastitis Causing Organisms

The objective of the analysis was to determine the sanitizing efficacy of the teat dip composition 1 (from Table 1 above) against *Staphylococcus aureus* ATCC 6538, *Escherichia coli* ATCC 11229, *Klebsiella pneumoniae* ATCC 4352, *Streptococcus agalactiae* ATCC 27056, *Streptococcus dysgalactiae* ATCC 27957, *Streptococcus uberis* ATCC 27958, *Enterobacter aerogenes* ATCC 13048, and *Pseudomonas aeruginosa* ATCC 15442 at a 15 second exposure time with a 10% milk challenge.

TEST METHOD:

The method used in this example generally followed AOAC method 960.09, with the following deviations: the exposure contact time was reduced to 15 seconds from 30 seconds. Additionally, a 10% whole milk soil challenge was prepared by adding 10 mls of raw whole milk to 90 mls of test product and mixed, and from which 99 ml aliquot is used for the test (with 1 ml of specified inoculum).

METHOD PARAMETERS:

Test Substance Name	Concentration	mL of Test Substance	mL of Diluent
KX-6128	100%	90	10

25	Test Systems:	<i>Staphylococcus aureus</i>	ATCC 6538
		<i>Escherichia coli</i>	ATCC 11229
		<i>Klebsiella pneumoniae</i>	ATCC 4352
		<i>Enterobacter aerogenes</i>	ATCC 13048
		<i>Streptococcus agalactiae</i>	ATCC 27956
		<i>Streptococcus dysgalactiae</i>	ATCC 27957

Streptococcus uberis
Pseudomonas aeruginosa

ATCC 27958
 ATCC 15442

5 **Test Temperature:** Ambient temperature

Exposure Time: 15 seconds

Neutralizer: Chambers

10 **Subculture Media:** Tryptone Glucose Extract Agar
 Brain Heart Infusion Agar (for *Streptococci*)

Incubation: 37°C for 48 hours

15

RESULTS:

Inoculum Numbers (CFU/mL)

Organism	Date	A	B	C	Average
<i>S. aureus</i> ATCC 6538	7/18/00	94 x 10 ⁶	91 x 10 ⁶	90 x 10 ⁶	9.2 x 10 ⁷
<i>E. coli</i> ATCC 11229	6/29/00	115 x 10 ⁶	105 x 10 ⁶	102 x 10 ⁶	1.1 x 10 ⁸
<i>E. aerogenes</i> ATCC 13048	6/29/00	70 x 10 ⁶	66 x 10 ⁶	64 x 10 ⁶	6.7 x 10 ⁷
<i>Klebsiella pneumoniae</i> ATCC 4352	7/18/00	168 x 10 ⁶	176 x 10 ⁶	126 x 10 ⁶	1.6 x 10 ⁸
<i>Streptococcus</i> <i>agalactiae</i> ATCC 27956	6/29/00	36 x 10 ⁶	58 x 10 ⁶	28 x 10 ⁶	4.1 x 10 ⁷
<i>Streptococcus</i> <i>dysgalactiae</i> ATCC 27957	7/18/00	74 x 10 ⁶	59 x 10 ⁶	44 x 10 ⁶	5.9 x 10 ⁷
<i>Streptococcus uberis</i> ATCC 27958	7/18/00	67 x 10 ⁶	76 x 10 ⁶	38 x 10 ⁶	6.0 x 10 ⁷
<i>Pseudomonas</i> <i>aeruginosa</i> ATCC 15442	7/18/00	84 x 10 ⁶	163 x 10 ⁶	134 x 10 ⁶	1.3 x 10 ⁸

20

Test Results

Test Substance	Test Organism	Survivors (CFU/mL)	Average Survivors (CFU/mL)	Log Reduction	Percent Reduction
KX-6128	<i>S. aureus</i>	<10, <10	<10	>6.96	>99.999
KX-6128	<i>E. coli</i>	<10, <10	<10	>7.04	>99.999
KX-6128	<i>E. aerogenes</i>	<10, <10	<10	>6.83	>99.999
KX-6128	<i>K. pneumoniae</i>	<10, <10	<10	>7.20	>99.999
KX-6128	<i>S. agalactiae</i>	<10, 2.0 x 10 ¹	1.5 x 10 ¹	>6.61	>99.999
KX-6128	<i>S. dysgalactiae</i>	<10, <10	<10	>6.77	>99.999
KX-6128	<i>S. uberis</i>	<10, <10	<10	>6.78	>99.999
KX-6128	<i>P. aeruginosa</i>	<10, <10	<10	>7.11	>99.999

5 CONCLUSIONS:

Teat Dip Formulation 1 (from table 1) achieved a >99.999 percent reduction with a 15 second exposure time at ambient temperature against *Staphylococcus aureus* ATCC 6538, *Escherichia coli* ATCC 11229, *Enterobacter aerogenes* ATCC 13048, *Klebsiella pneumoniae* ATCC 4352, *Streptococcus agalactiae* ATCC 27956, *Streptococcus dysgalactiae* ATCC 27958, *Streptococcus uberis* ATCC 27958, and *Pseudomonas aeruginosa* ATCC 15442. This percent reduction was unexpectedly high.

From the foregoing detailed description and examples, it will be evident that modifications and variations can be made to the compositions and methods of the invention without departing from the spirit and scope of the invention. Therefore, it is intended that all modifications made to the invention without departing from the spirit and scope of the invention come within the scope of the appended claims.

WHAT IS CLAIMED IS:

1. An antimicrobial composition comprising:
in the range of 0.01 to 5 wt. % of a C6-C12 fatty acid; and
a carrier medium including a freezing point depressant component, wherein
5 the freezing point depressant component makes up greater than 60 wt. % of the total
composition.
2. The antimicrobial composition of claim 1, wherein the fatty acid is C7-C9.
- 10 3. The antimicrobial composition of claim 1, wherein the fatty acid is heptanoic
acid.
4. The antimicrobial composition of claim 1, wherein the freezing point
depressant component is selected from polyol or mixtures thereof.
- 15 5. The antimicrobial composition of claim 4, wherein the freezing point
depressant component is selected from propylene glycol, glycerin, and mixtures
thereof.
- 20 6. The antimicrobial composition of claim 5, wherein the freezing point
depressant component is a mixture of propylene glycol and glycerin.

7. The antimicrobial composition of claim 1, wherein the composition has a freezing point of below 32°F.

8. The antimicrobial composition of claim 1, wherein the composition has a
5 freezing point of below 20°F.

9. The antimicrobial composition of claim 1, wherein the composition has a freezing point of below 10°F.

10 10. The antimicrobial composition of claim 1, wherein the composition has a freezing point of below 0°F.

11. The antimicrobial composition of claim 1, wherein the composition has a freezing point of below -10°F.

15

12. The antimicrobial composition of claim 1, wherein the composition has a freezing point of below -20°F.

14. The antimicrobial composition of claim 1, wherein the freezing point
20 depressant component makes up greater than 65 wt. % of the total composition.

15. The antimicrobial composition of claim 1, wherein the freezing point depressant component makes up greater than 70 wt. % of the total composition.

16. The antimicrobial composition of claim 1, wherein the freezing point depressant component makes up greater than 75 wt. % of the total composition.

5 17. An antimicrobial composition comprising:
in the range of 0.01 to 5 wt. % of heptanoic acid; and
greater than 60 wt. % of a freezing point depressant component comprising propylene glycol and glycerin.

10 18. An antimicrobial composition comprising:
an antimicrobial component consisting essentially of heptanoic acid, and
a carrier medium.

15 19. A method for controlling mastitis in milk producing animals, the method comprising:
applying an antimicrobial composition to a teat of an animal wherein the antimicrobial composition comprises in the range of 0.01 to 5 wt. % of a C6-C12 fatty acid and a carrier medium including a freezing point depressant component, wherein the freezing point depressant component comprises greater than 60 wt. % of the
20 composition.

20. The method of claim 19, wherein the antimicrobial composition is applied in environmental temperatures of below 40°F or is applied to the teat of an animal that

will be exposed to environmental temperatures of below 40°F within 12 hours of the application.

21. The method of claim 20, wherein the environmental temperatures of below
5 30°F.

22. The method of claim 20, wherein the environmental temperatures of below
20°F.

10 23. The method of claim 20, wherein the environmental temperatures of below
10°F.

24. The method of claim 19, wherein the fatty acid is C7-C9.

15 25. The method of claim 19, wherein the fatty acid is heptanoic acid.

26. The method of claim 19, wherein the freezing point depressant component is
selected from polyols or mixtures thereof.

20 27. The method of claim 26, wherein the freezing point depressant component is
selected from the group consisting of propylene glycol, glycerin, and mixtures
thereof.

28. The method of claim 27, wherein, wherein the freezing point depressant component is a mixture of propylene glycol and glycerin.

29. The method of claim 19, wherein the composition has a freezing point of
5 below 32°F.

30. The method of claim 19, wherein the composition has a freezing point of below 20°F.

10 31. The method of claim 19, wherein the composition has a freezing point of below 10°F.

32. The method of claim 19, wherein the composition has a freezing point of below 0°F.

15

33. The method of claim 19, wherein the composition has a freezing point of below -10°F.

34. The method of claim 19, wherein the composition has a freezing point of
20 below -20°F.

35. The method of claim 19, wherein the freezing point depressant component makes up greater than 65 wt. % of the total composition.

Abstract

Antimicrobial compositions containing a carboxylic acid, for example, a fatty acid, and a carrier medium including a freezing point depressant are disclosed. The
5 compositions can be formulated for use as a teat dip, for use on milk producing animals. In one particularly advantageous embodiment, a composition is formulated as a teat dip and includes suitable emollients, skin conditioners and lubricants.

00676630-100300

MERCHANT & GOULD P.C.

United States Patent Application

COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; that

I verily believe I am the original, first and sole inventor (if only one name is listed below) or a joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: ANTIMICROBIAL COMPOSITIONS FORMULATED FOR USE IN COLD TEMPERATURE CONDITIONS AND METHODS OF USE THEREOF

The specification of which

- a. ☒ is attached hereto
b. ☐ was filed on _____ as application serial no. _____ and was amended on _____ (if applicable) (in the case of a PCT-filed application) described and claimed in international no. _____ filed _____ and as amended on _____ (if any), which I have reviewed and for which I solicit a United States patent.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, § 1.56 (attached hereto).

I hereby claim foreign priority benefits under Title 35, United States Code, § 119/365 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on the basis of which priority is claimed:

- a. ☒ no such applications have been filed.
b. ☐ such applications have been filed as follows:

FOREIGN APPLICATION(S), IF ANY, CLAIMING PRIORITY UNDER 35 USC § 119			
COUNTRY	APPLICATION NUMBER	DATE OF FILING (day, month, year)	DATE OF ISSUE (day, month, year)
ALL FOREIGN APPLICATION(S), IF ANY, FILED BEFORE THE PRIORITY APPLICATION(S)			
COUNTRY	APPLICATION NUMBER	DATE OF FILING (day, month, year)	DATE OF ISSUE (day, month, year)

I hereby claim the benefit under Title 35, United States Code, § 120/365 of any United States and PCT international application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. APPLICATION NUMBER	DATE OF FILING (day, month, year)	STATUS (patented, pending, abandoned)

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below:

U.S. PROVISIONAL APPLICATION NUMBER	DATE OF FILING (Day, Month, Year)

I hereby appoint the following attorney(s) and/or patent agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected herewith:

Albrecht, John W.	Reg. No. 40,481	Leon, Andrew J.	Reg. No. P-46,869
Ali, M. Jeffer	Reg. No. 46,359	Leonard, Christopher J.	Reg. No. 41,940
Anderson, Gregg I.	Reg. No. 28,828	Liepa, Mara E.	Reg. No. 40,066
Batzli, Brian H.	Reg. No. 32,960	Lindquist, Timothy A.	Reg. No. 40,701
Beard, John L.	Reg. No. 27,612	Lycke, Lawrence E.	Reg. No. 38,540
Berns, John M.	Reg. No. 43,496	McAuley, Steven A.	Reg. No. 46,084
Black, Bruce E.	Reg. No. 41,622	McDonald, Daniel W.	Reg. No. 32,044
Branch, John W.	Reg. No. 41,633	McIntyre, Jr., William F.	Reg. No. 44,921
Bremer, Dennis C.	Reg. No. 40,528	Mitchem, M. Todd	Reg. No. 40,731
Bruess, Steven C.	Reg. No. 34,130	Mueller, Douglas P.	Reg. No. 30,300
Byrne, Linda M.	Reg. No. 32,404	Nichols, A. Shane	Reg. No. 43,836
Campbell, Keith	Reg. No. P-46,597	Pauly, Daniel M.	Reg. No. 40,123
Carlson, Alan G.	Reg. No. 25,959	Phillips, Bryan K.	Reg. No. P-46,990
Caspers, Philip P.	Reg. No. 33,227	Phillips, John B.	Reg. No. 37,206
Chiapetta, James R.	Reg. No. 39,634	Plunkett, Theodore	Reg. No. 37,209
Clifford, John A.	Reg. No. 30,247	Prendergast, Paul	Reg. No. 46,068
Daignault, Ronald A.	Reg. No. 25,968	Pytel, Melissa J.	Reg. No. 41,512
Daley, Dennis R.	Reg. No. 34,994	Qualey, Terry	Reg. No. 25,148
Dalglish, Leslie E.	Reg. No. 40,579	Reich, John C.	Reg. No. 37,703
Daulton, Julie R.	Reg. No. 36,414	Reiland, Earl D.	Reg. No. 25,767
DeVries Smith, Katherine M.	Reg. No. 42,157	Samuels, Lisa A.	Reg. No. 43,080
DiPietro, Mark J.	Reg. No. 28,707	Schmaltz, David G.	Reg. No. 39,828
Edell, Robert T.	Reg. No. 20,187	Schuman, Mark D.	Reg. No. 31,197
Epp Ryan, Sandra	Reg. No. 39,667	Schumann, Michael D.	Reg. No. 30,422
Glance, Robert J.	Reg. No. 40,620	Scull, Timothy B.	Reg. No. 42,137
Goggin, Matthew J.	Reg. No. 44,125	Sebald, Gregory A.	Reg. No. 33,280
Golla, Charles E.	Reg. No. 26,896	Skoog, Mark T.	Reg. No. 40,178
Gorman, Alan G.	Reg. No. 38,472	Spellman, Steven J.	Reg. No. 45,124
Gould, John D.	Reg. No. 18,223	Stoll-DeBell, Kirstin L.	Reg. No. 43,164
Gregson, Richard	Reg. No. 41,804	Sumner, John P.	Reg. No. 29,114
Gresens, John J.	Reg. No. 33,112	Swenson, Erik G.	Reg. No. 45,147
Hamer, Samuel A.	Reg. No. P-46,754	Tellekson, David K.	Reg. No. 32,314
Hamre, Curtis B.	Reg. No. 29,165	Trembath, Jon R.	Reg. No. 38,344
Harrison, Kevin C.	Reg. No. P-46,759	Tuchman, Ido	Reg. No. 45,924
Hertzberg, Brett A.	Reg. No. 42,660	Underhill, Albert L.	Reg. No. 27,403
Hillson, Randall A.	Reg. No. 31,838	Vandenburgh, J. Derek	Reg. No. 32,179
Holzer, Jr., Richard J.	Reg. No. 42,668	Wahl, John R.	Reg. No. 33,044
Johnston, Scott W.	Reg. No. 39,721	Weaver, Karrie G.	Reg. No. 43,245
Kadievitch, Natalie D.	Reg. No. 34,196	Welter, Paul A.	Reg. No. 20,890
Karjeker, Shaukat	Reg. No. 34,049	Whipps, Brian	Reg. No. 43,261
Kastelic, Joseph M.	Reg. No. 37,160	Whitaker, John E.	Reg. No. 42,222
Kettelberger, Denise	Reg. No. 33,924	Wickhem, J. Scot	Reg. No. 41,376
Keys, Jeramie J.	Reg. No. 42,724	Williams, Douglas J.	Reg. No. 27,054
Knearl, Homer L.	Reg. No. 21,197	Withers, James D.	Reg. No. 40,376
Kowalchyk, Alan W.	Reg. No. 31,535	Witt, Jonelle	Reg. No. 41,980
Kowalchyk, Katherine M.	Reg. No. 36,848	Wu, Tong	Reg. No. 43,361
Lacy, Paul E.	Reg. No. 38,946	Xu, Min S.	Reg. No. 39,536
Larson, James A.	Reg. No. 40,443	Zeuli, Anthony R.	Reg. No. 45,255

I hereby authorize them to act and rely on instructions from and communicate directly with the person/assignee/attorney/firm/ organization who/which first sends/sent this case to them and by whom/which I hereby declare that I have consented after full disclosure to be represented unless/until I instruct Merchant & Gould P.C. to the contrary.

Please direct all correspondence in this case to Merchant & Gould P.C. at the address indicated below:

Merchant & Gould P.C.
P.O. Box 2903
Minneapolis, MN 55402-0903



I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2	Full Name Of Inventor	Family Name RICHTER	First Given Name FRANCIS	Second Given Name LAWRENCE
0	Residence & Citizenship	City LINO LAKES	State or Foreign Country MINNESOTA	Country of Citizenship USA
1	Post Office Address	Post Office Address 6707 SHERMAN LAKE ROAD	City LINO LAKES	State & Zip Code/Country MINNESOTA 55038/USA
Signature of Inventor 201:				Date:
2	Full Name Of Inventor	Family Name REINHARDT	First Given Name DUANE	Second Given Name JOSEPH
0	Residence & Citizenship	City MAPLEWOOD	State or Foreign Country MINNESOTA	Country of Citizenship USA
2	Post Office Address	Post Office Address 2376 MAILAND ROAD	City MAPLEWOOD	State & Zip Code/Country MINNESOTA 55119/USA
Signature of Inventor 202:				Date:

§ 1.56 Duty to disclose information material to patentability.

(a) A patent by its very nature is affected with a public interest. The public interest is best served, and the most effective patent examination occurs when, at the time an application is being examined, the Office is aware of and evaluates the teachings of all information material to patentability. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is canceled or withdrawn from consideration, or the application becomes abandoned. Information material to the patentability of a claim that is canceled or withdrawn from consideration need not be submitted if the information is not material to the patentability of any claim remaining under consideration in the application. There is no duty to submit information which is not material to the patentability of any existing claim. The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability of any claim issued in a patent was cited by the Office or submitted to the Office in the manner prescribed by §§ 1.97(b)-(d) and 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was practiced or attempted or the duty of disclosure was violated through bad faith or intentional misconduct. The Office encourages applicants to carefully examine:

(1) prior art cited in search reports of a foreign patent office in a counterpart application, and

(2) the closest information over which individuals associated with the filing or prosecution of a patent application believe any pending claim patentably defines, to make sure that any material information contained therein is disclosed to the Office.

(b) Under this section, information is material to patentability when it is not cumulative to information already of record or being made of record in the application, and

(1) It establishes, by itself or in combination with other information, a prima facie case of unpatentability of a claim;

(2) It refutes, or is inconsistent with, a position the applicant takes in:

(i) Opposing an argument of unpatentability relied on by the Office, or

(ii) Asserting an argument of patentability.

A prima facie case of unpatentability is established when the information compels a conclusion that a claim is unpatentable under the preponderance of evidence, burden-of-proof standard, giving each term in the claim its broadest reasonable construction consistent with the specification, and before any consideration is given to evidence which may be submitted in an attempt to establish a contrary conclusion of patentability.

(c) Individuals associated with the filing or prosecution of a patent application within the meaning of this section are:

(1) Each inventor named in the application:

(2) Each attorney or agent who prepares or prosecutes the application; and

(3) Every other person who is substantively involved in the preparation or prosecution of the application and who is associated with the inventor, with the assignee or with anyone to whom there is an obligation to assign the application.

(d) Individuals other than the attorney, agent or inventor may comply with this section by disclosing information to the attorney, agent, or inventor.